# YUTREPIA (treprostinil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/treprostinil

> The FDA approved YUTREPIA (treprostinil), sponsored by UNITED THERAPEUTICS Corp (UTHR), on May 23, 2025 for PAH and PH-ILD in May 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is YUTREPIA (treprostinil) FDA approved?

Yes. The FDA approved YUTREPIA (treprostinil), sponsored by UNITED THERAPEUTICS Corp (UTHR), on May 23, 2025 for PAH and PH-ILD in May 2025. SEC Form 8-K: "As previously disclosed, the FDA granted approval of YUTREPIA™ for the treatment of PAH and PH-ILD on May 23, 2025." [Calendar and source filings](https://sec-api.dev/pdufa/treprostinil)

Source: SEC Form 8-K, accession 0001104659-25-055180, https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_8k.htm (retrieved 2026-11-12). Last confirmed 2026-08-12. Cite: https://sec-api.dev/pdufa/treprostinil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | YUTREPIA (treprostinil) |
| Codes |  |
| Sponsor | UNITED THERAPEUTICS Corp (UTHR) https://sec-api.dev/companies/uthr/catalysts |
| Indications | pah and ph-ild in may 2025, pah and ph-ild, [pulmonary arterial hypertension](https://sec-api.dev/indications/pulmonary-arterial-hypertension), rare cardiopulmonary disease, rare cardiopulmonary disease, today |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### October 7, 2016: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22208276_2018_Orig1s000OtherActionLtrs.pdf%22

### June 2, 2017: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22208276_2018_Orig1s000OtherActionLtrs.pdf%22

### October 15, 2021: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22214324_2022_Orig1s000OtherActionLtrs.pdf%22

### Jul 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-19, last confirmed 2025-03-19.
- SEC Form 10-K (accession 0001558370-25-003237): "In July 2023, we filed an amendment to our NDA to add PH-ILD to the labeled indications for YUTREPIA." https://www.sec.gov/Archives/edgar/data/1819576/000155837025003237/lqda-20241231x10k.htm

### Sep 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-006838): "In September 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA's acceptance of the Company's amended NDA for review." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006838/lqda-20241231xex99d1.htm

### March 28, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: rare cardiopulmonary disease, today.
- First seen 2025-03-28, last confirmed 2025-05-05.
- SEC Form 8-K (accession 0001104659-25-044345): "As previously disclosed on March 28, 2025, the FDA has accepted the Company's NDA resubmission for YUTREPIA to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and has set a Prescription Drug User Fee Act ("PDUFA") goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029401): "MORRISVILLE, N.C., March 28, 2025 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil)" https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788d1_ex99-1.htm

### May 23, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: PAH and PH-ILD in May 2025.
- First seen 2025-05-23, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-052454): "Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA™ (treprostinil)" https://www.sec.gov/Archives/edgar/data/1819576/000110465925052454/tm2516078d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-055180): "As previously disclosed, the FDA granted approval of YUTREPIA™ for the treatment of PAH and PH-ILD on May 23, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-055180): "FDA approved YUTREPIA on May 23, 2025" https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-055180): "This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)." https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-094410): "We are primarily dependent on the success of YUTREPIA, for which we received FDA approval in May 2025, and L606, and these products and product candidates may fail to receive or to maintain marketing approval (in a timely manner or at all) for some or all of the indications for which we have received or are seeking approval or may not be commercialized successfully." https://www.sec.gov/Archives/edgar/data/1819576/000110465926094410/lqda-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-25-105215): "We received final FDA approval of our NDA for YUTREPIA for the treatment of PAH and PH-ILD in May 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925105215/lqda-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011139): "We received final FDA approval of our NDA for YUTREPIA for the treatment of PAH and PH-ILD in May 2025." https://www.sec.gov/Archives/edgar/data/1819576/000155837025011139/lqda-20250630x10q.htm

### May 24, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-28, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-046935): "Does not impact FDA's ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025" https://www.sec.gov/Archives/edgar/data/1819576/000110465925046935/tm2514743d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045850): "Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025" https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-044345): "As previously disclosed on March 28, 2025, the FDA has accepted the Company's NDA resubmission for YUTREPIA to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and has set a Prescription Drug User Fee Act ("PDUFA") goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-044345): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the YUTREPIA NDA of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-006848): "We have resubmitted the YUTREPIA NDA for final approval, and the FDA has confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued in August 2024 and set a PDUFA goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006848/lqda-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006848): "Although the exclusivity period will expire on May 23, 2025 and the FDA has set a PDUFA goal date of May 24, 2025, the FDA may need more time to review and approve our NDA or may otherwise delay taking action on the YUTREPIA NDA." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006848/lqda-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029401): "FDA sets PDUFA goal date of May 24, 2025" https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-029401): "Drug User Fee Act ("PDUFA") goal date of May 24, 2025" https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788-1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029401): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-006848): "The FDA has confirmed that the resubmission was a complete, Class 1 response to the previous action letter and has set a Prescription Drug User Fee Act ("PDUFA") goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006848/lqda-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006848): "As a result of this litigation instituted to date and potential litigation that may be instituted in the future, final FDA approval of YUTREPIA for PAH and/or PH-ILD may be further delayed even past the PDUFA goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006848/lqda-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006848): "If prolonged government shutdowns, inadequate funding, loss of employees (including those employees who were previously involved in the review of the NDA for YUTREPIA), changes in regulations or policies by the new U.S. administration or other disruptions were to occur at the FDA, a final FDA decision with respect to the NDA for YUTREPIA for PAH and PH-ILD may be further delayed even past the PDUFA goal date of May 24, 2025." https://www.sec.gov/Archives/edgar/data/1819576/000155837025006848/lqda-20250331x10q.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-09-03, last confirmed 2026-09-03.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-104929): "Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1819576/000110465926104929/tm2624724d1_ex99-1.htm

## Same indication

- [Seralutinib](https://sec-api.dev/pdufa/seralutinib) (GOSS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/treprostinil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "YUTREPIA (treprostinil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/treprostinil

```bibtex
@misc{secapidev_pdufa_treprostinil_20261116,
  title        = {YUTREPIA (treprostinil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/treprostinil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_treprostinil_20261116","title":"YUTREPIA (treprostinil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/treprostinil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
